WO2019146669A1 - INHIBITEUR DE mTOR - Google Patents

INHIBITEUR DE mTOR Download PDF

Info

Publication number
WO2019146669A1
WO2019146669A1 PCT/JP2019/002187 JP2019002187W WO2019146669A1 WO 2019146669 A1 WO2019146669 A1 WO 2019146669A1 JP 2019002187 W JP2019002187 W JP 2019002187W WO 2019146669 A1 WO2019146669 A1 WO 2019146669A1
Authority
WO
WIPO (PCT)
Prior art keywords
pomegranate
royal jelly
extract
composition
propolis
Prior art date
Application number
PCT/JP2019/002187
Other languages
English (en)
Japanese (ja)
Inventor
博 井ノ岡
颯 板谷
礼訓 八巻
暢章 奥村
倫世 結石
Original Assignee
株式会社山田養蜂場本社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社山田養蜂場本社 filed Critical 株式会社山田養蜂場本社
Priority to JP2019567128A priority Critical patent/JP7256542B2/ja
Priority to CN201980009955.4A priority patent/CN111655226A/zh
Publication of WO2019146669A1 publication Critical patent/WO2019146669A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a composition having an mTOR inhibitory action. Furthermore, the present invention relates to mTOR inhibitors, anti-aging, anti-fatigue, anti-stress, metabolic improvement, diet, moisturizing, skin amelioration or gloss improvement, cognitive function deterioration prevention, immunosuppression The present invention relates to a composition for anti-allergy, for preventing cancer, or for suppressing the progression of cancer.
  • mTOR (mechanistic (mammalian) target of rapamycin) is a type of protein kinase involved in intracellular signal transduction in animals such as mammals, and important for protein translation, autophagy, immunoregulation, cytoskeleton regulation, gene transcription, etc. It works well and is deeply involved in fundamental life phenomena such as cell growth, division and death. mTOR is a protein found as an intracellular target of rapamycin that exhibits strong immunosuppressive action and anticancer action, and has been revealed to be a large serine-threonine kinase with a molecular weight of 290,000.
  • mTORC1 and mTORC2 regulate multiple in vivo reactions, and in particular, mTORC1 plays an important role in life maintenance, such as biosynthesis regulation in ribosomes, biosynthesis of proteins as well as nucleic acids and lipids.
  • Rapamycin which mainly controls mTORC1 has been scientifically confirmed to be effective in prolonging life in many organisms from nematodes to rodents, and clinical trials for life extension have been conducted in primates including humans. It is done.
  • autophagy autophagy enhancement to recycle intracellular organs, browning of adipocytes to enhance metabolism, suppression of cognitive function decline such as reduction of ⁇ -amyloid deposition, immunosuppression such as suppression of inflammatory cytokine secretion, etc. It has various functions such as growth suppression of various cancer cells (Non-patent documents 1 and 2).
  • Non-Patent Document 3 the inhibition of mTORC1 increases the production of filaggrin, a moisturizing regulator, through increased expression of cathepsin H. From this, by inhibiting mTOR, effects such as anti-skin aging and moisturizing can be expected (Non-Patent Document 3).
  • Pomegranate is the oldest cultivated fruit tree in the world, and there are many seeds in the fruit, and some kinds of clothing are consumed around the seeds. Pomegranate is eaten raw as well as juice and syrup. Patent Documents 1 to 3 report various effects of such pomegranate.
  • Patent Document 1 reports an antiaging agent containing coenzyme Q10 and a pomegranate compound. As described above, it is described that by using coenzyme Q10 in combination with a pomegranate compound, it is possible to obtain a synergistic effect of suppressing aging and to prevent quality deterioration.
  • Patent Document 2 a composition for external use on the skin is reported using a compound herbal extract composed of stone peels, apricot kernel, yokjin kernel, three white herbs and shiso leaf as an active ingredient. And, the compound herbal extract is described to have skin moisturizing, strengthening of skin barrier function, and differentiation induction effect of skin keratinocytes.
  • Patent Document 3 reports a composition for preventing skin aging, which contains an ultraviolet ray damage inhibitor (such as loquat extract) and a near infrared ray damage inhibitor (such as pomegranate extract). It is described that the combination of the ultraviolet ray damage inhibitor and the near infrared ray damage inhibitor can make a significant contribution to the prevention of skin aging.
  • an ultraviolet ray damage inhibitor such as loquat extract
  • a near infrared ray damage inhibitor such as pomegranate extract
  • An object of the present invention is to provide a composition having excellent mTOR inhibitory activity. Furthermore, the present invention relates to mTOR inhibitors, anti-aging, anti-fatigue, anti-stress, metabolic improvement, diet, moisturizing, skin amelioration or gloss improvement, cognitive function deterioration prevention, immunosuppression It is an object of the present invention to provide a composition for anti-allergy, for preventing cancer, or for suppressing the progression of cancer.
  • the present inventors added pomegranate material to royal jelly or propolis, and added each activity at least about 3 to 4 times stronger than the (additive average) activity. It has been found that mTOR inhibitory activity can be obtained, that is, synergistic effects can be obtained.
  • the present invention has been completed based on these findings and has been repeatedly studied, and provides the following composition, an mTOR inhibitor and the like.
  • Item 1 Cosmetics, food and drink, medicines, or quasi-drugs, A composition comprising royal jelly and pomegranate peel or an extract thereof.
  • Item 2. Cosmetics, food and drink, medicines, or quasi-drugs, A composition comprising propolis and pomegranate or an extract thereof.
  • Item 3. Royal jelly and / or propolis, and an mTOR inhibitor comprising pomegranate or an extract thereof.
  • Item 4. Containing royal jelly and / or propolis, and pomegranate or its extract, anti-aging, anti-fatigue, anti-stress, metabolic improvement, diet, moisturizing, skin amelioration or gloss improvement, cognitive function decline prevention Composition for immunosuppression, anti-allergy, cancer prevention, or cancer progression suppression.
  • Item 5. Item 5.
  • composition according to item 4 which is a cosmetic, food and drink, medicine, or quasi-drug.
  • Item 6. The composition according to Item 2, 4 or 5, wherein the pomegranate is pomegranate peel, the mTOR inhibitor according to Item 3.
  • Item 7. The composition according to Item 1, 4, 5, or 6, wherein the royal jelly is an enzyme-treated royal jelly, or the mTOR inhibitor according to Item 3 or 6.
  • Item 8. A composition for inhibiting mTOR comprising royal jelly and / or propolis, and pomegranate or an extract thereof.
  • Item 9. A method of inhibiting mTOR, comprising the step of administering an effective amount of royal jelly and / or propolis, and pomegranate or an extract thereof to a mammal.
  • Item 10 Aging suppression method, fatigue improvement method, stress improvement method, metabolism improvement method, diet method, moisturizing method, skin moisturizing method comprising a step of administering to a mammal an effective amount of royal jelly and / or propolis and pomegranate or an extract thereof Or the gloss improvement method, the cognitive function fall prevention method, the immunosuppression method, the antiallergic method, the cancer prevention method, or the cancer progression suppression method.
  • Item 11 Use of a composition comprising royal jelly and / or propolis, and pomegranate or an extract thereof in the manufacture of mTOR inhibitors.
  • Item 15. The composition according to item 8, the method according to item 9 or 10, or the use according to any one of items 11 to 14, wherein the pomegranate is pomegranate peel.
  • Item 16 Item 16.
  • the composition of the present invention has excellent mTOR inhibitory activity due to the synergistic effect of royal jelly or propolis and pomegranate or its extract. Therefore, the combination of royal jelly or propolis with pomegranate or its extract is an mTOR inhibitor, and for anti-aging, anti-fatigue, anti-stress, metabolic improvement, diet, moisturizing, skin amelioration or gloss improvement It is useful as a component of a composition for preventing cognitive function deterioration, for immunosuppression, for anti-allergy, for cancer prevention, or for suppressing cancer progression.
  • extracts of royal jelly, propolis, and pomegranate are highly safe because they are components of natural origin.
  • compositions and mTOR inhibitors according to the invention are characterized in that they comprise royal jelly and / or propolis and pomegranate or an extract thereof.
  • Royal jelly is a milky white jelly-like substance formed by mixing secretions which are released from the hypopharyngeal gland and the major glands by working bees of 3 to 12 days among bees.
  • the main physiologically active ingredients in royal jelly include, for example, organic acids such as 10-hydroxydecenoic acid (hereinafter referred to as "decenic acid”) unique to royal jelly, proteins, lipids, saccharides, vitamin Bs, Vitamins such as folic acid, nicotinic acid and pantothenic acid, various minerals, and the like can be mentioned.
  • the royal jelly in the present invention includes raw royal jelly, dried royal jelly, dried royal jelly powder, enzyme-treated royal jelly, royal jelly extract, royal jelly fermented product and the like.
  • the royal jelly may be produced in any of European countries, Oceania countries, the United States, Brazil, Japan, China, and other Asian countries.
  • the dried royal jelly powder is obtained by drying and pulverizing raw royal jelly.
  • Enzyme-treated royal jelly is obtained by treating royal jelly with a protease (protease).
  • a protease protease
  • it is a hypoallergenic enzyme-treated royal jelly in which an allergic reaction caused by a protein contained in royal jelly is suppressed by protease treatment. Therefore, the enzyme-treated royal jelly may contain, in addition to the protease decomposition product of the protein contained in royal jelly, organic acids such as decenoic acid described above, lipids, saccharides, vitamins, and various minerals.
  • the royal jelly used for producing the enzyme-treated royal jelly is not limited and includes, for example, fresh royal jelly, royal jelly powder obtained by drying and powdered fresh royal jelly, or one obtained by extracting fresh royal jelly with water or water-containing ethanol or the like.
  • the enzyme-degraded royal jelly can be produced by treating a royal jelly raw material with at least an enzyme having endopeptidase activity, an enzyme having at least exopeptidase activity, and / or an enzyme having endopeptidase activity and exopeptidase activity.
  • proteolytic enzyme having at least endopeptidase activity
  • animal origin for example, trypsin, chymotrypsin etc.
  • plant origin eg papain etc.
  • microorganism origin eg lactic acid bacteria, yeast, mold, Bacillus subtilis, actinomycete etc.
  • proteolytic enzyme having at least exopeptidase activity
  • carboxypeptidase aminopeptidase
  • exopeptidase of microorganism origin eg, lactic acid bacteria, Aspergillus genus bacteria, Rhizopus genus bacteria etc.
  • pancreatin e.g., pepsin etc having endopeptidase activity
  • pepsin etc having endopeptidase activity
  • enzymes having both exopeptidase activity and endopeptidase activity include Streptomyces griseus-produced peptidase (trade name: Actinase AS), Aspergillus oryzae (Aspergillus) oryzae)
  • the produced peptidase (trade name: Protease A, flavorzyme), Aspergillus melleus produced peptidase (trade name: Protease P) is also a preferred example of an enzyme having exoprotease activity.
  • Aspergillus oryzae Production peptidases (trade names: Umamizyme G, Promod 192P, Promod 194P, Sumizyme FLAP), Aspergillus sojae producing peptidases (trade name: Sternzyme B15024), Aspergillus sp. Hydrolase P), Rhizopus oryzae (Rhizopus oryzae) produce peptidase (trade name: peptidase R) can be mentioned.
  • Bacillus subtilis-produced peptidase (trade name: Orientase 22BF, nucleicin), Bacillus licheniformis-produced peptidase (trade name: Alcalase) ), Bacillus stearothermophilus produced peptidase (trade name: Protease S), Bacillus amyloliquefaciens produced peptidase (trade name: Neutrase), Bacillus genus produced peptidase (trade name) : Protamex) can be mentioned.
  • the enzyme treatment for reducing the allergenicity of royal jelly can be carried out according to, for example, the descriptions of JP-A-2007-295919 and JP-A-2007-295920.
  • the royal jelly extract is obtained by extracting royal jelly (including fresh, dried and ground products) with water or water-containing ethanol or the like.
  • the royal jelly fermented product can be produced by a conventional method using microorganisms such as yeast and lactic acid bacteria.
  • Propolis is a resinous or waxy substance that constitutes the nest wall of a bee nest.
  • propolis may be derived from any origin and plant, for example, Brazil, China, European countries, Oceania, America and the like. Therefore, any propolis such as alexrin, super green, eucalyptus, ultra green, etc. can be used.
  • the propolis in the present invention includes, for example, raw propolis, crushed product thereof, supercritical extract, extract with water or hydrophilic organic solvent, powder obtained by pulverizing the extract, granular form obtained by granulating the powder, etc. Is included.
  • the hydrophilic organic solvent extract is preferable because the active ingredient of propolis is efficiently extracted in a short time and in a well-balanced manner, and large-scale equipment is not necessary when scaling up.
  • hydrophilic organic solvent extract examples include lower alcohols such as ethanol, methanol and propanol, and ethanol is particularly preferable.
  • propolis block, alcohol-washed propolis block, etc. can be used, and extraction efficiency can be improved by using a propolis block cut or crushed to a suitable size.
  • Pomegranate (Pomegranate or its extract) Pomegranate (Sekigan) is a scientific name Punica granatum (Punica granatum L.), and is a deciduous tall tree belonging to the pomegranate.
  • the site of the pomegranate to be used is not particularly limited, and includes, for example, a skin, a seed, a flesh, a leaf, a branch, a bark, a trunk, a stem, a flower, a root, a root bark and the like . Above all, it is desirable to use pomegranate peel. As a component contained in pomegranate peel, ellagic acid etc. are mentioned.
  • pomegranate for example, those in a non-dried raw state, those in a dried state (by sun-drying etc.), those in a heat-dried state, etc. can be used.
  • pomegranate can be used as a raw material in the original uncut or crushed state, and sliced or crushed can also be used as a raw material.
  • Pomegranate extract can be used in the present invention, and the extract may be extracted from pomegranate by any method.
  • the method for obtaining the extract of pomegranate is not particularly limited, and examples thereof include a method of extraction using a polar solvent, and a method of extraction using supercritical extraction with carbon dioxide and the like. Extracts of pomegranate (especially pomegranate peel) may contain ellagic acid.
  • examples of the extraction solvent to be used include water, lower alcohol (methanol, ethanol, n-propanol, isopropanol etc.), ketones (acetone, methyl ethyl ketone, methyl butyl ketone etc.), esters (acetic acid) Methyl, ethyl acetate and the like, glycols (ethylene glycol, propylene glycol and the like), glycerin, tetrahydrofuran, acetonitrile, acetic acid, propionic acid, acetamide, dimethylformamide, dimethylsulfoxide and the like can be mentioned.
  • lower alcohol methanol, ethanol, n-propanol, isopropanol etc.
  • ketones acetone, methyl ethyl ketone, methyl butyl ketone etc.
  • esters acetic acid Methyl, ethyl acetate and the like
  • glycols ethylene glycol, propylene
  • extraction solvents may be used alone or in combination of two or more as a mixture.
  • water, lower alcohol (preferably ethanol) or a mixture thereof (hydroalcohol, preferably hydroethanol) is used.
  • hydroalcohol preferably hydroethanol
  • the alcohol concentration is preferably, but not limited to, 20 to 90% by volume, particularly 40 to 80% by volume.
  • Extraction is performed by adding part or all of pomegranate to a solvent, extracting from immersion for 30 minutes to about 3 days at 0 ° C. to a temperature at which the solvent boils, usually at a temperature of 100 ° C. or less, and then insoluble matter The removal can be easily performed.
  • the solvent extract thus obtained can be used as it is, and if necessary, ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography Purification may be further performed by (HPLC), dialysis methods, combinations thereof and the like.
  • the solvent extract can also be concentrated and subjected to drying treatment such as lyophilization and spray drying. Here, concentration, lyophilization and spray drying can be performed according to a conventional method.
  • the ratio of the pomegranate or its extract contained in the composition of the present invention and the mTOR inhibitor is not particularly limited as long as the effects of the present invention can be obtained, and can be appropriately adjusted according to the final form etc. It is possible to suitably select from the range of preferably 1 to 80% by mass, more preferably 2 to 50% by mass.
  • royal jelly is preferably 0.01 to 100 parts by mass, more preferably 0.1 to 70 parts by mass, still more preferably 1 to 10 parts by mass with respect to 1 part by mass of pomegranate or its extract. 50 parts by mass are included.
  • propolis is preferably 0.01 to 100 parts by mass, more preferably 0.1 to 70 parts by mass, still more preferably 1 to 50 parts by mass with respect to 1 part by mass of pomegranate or its extract. 50 parts by mass are included.
  • composition of the present invention and the mTOR inhibitor known components other than the above can be appropriately blended, as long as the effects of the present invention are not impaired.
  • composition and the mTOR inhibitor of the present invention are cosmetic, food and drink (especially food and drink for health, health maintenance, promotion etc. (eg, health food, functional food, nutrition composition, nutrition) It can be used as a supplement, a supplement, a health food, a food for specified health use, a nutritive function food, or a functional indication food), a quasi-drug, a medicine and the like.
  • composition of the present invention and the mTOR inhibitor have mTOR inhibitory action, anti-aging action, anti-fatigue action, anti-stress action, metabolic improvement action, diet action, moisturizing action, skin ache or gloss improving action, cognitive function decline
  • mTOR inhibitory action anti-aging action, anti-fatigue action, anti-stress action, metabolic improvement action, diet action, moisturizing action, skin ache or gloss improving action, cognitive function decline
  • additives for imparting a preventive action, an immunosuppressive action, an antiallergic action, a cancer preventive action, and a cancer progression suppressive action is also included.
  • ingredients usually used for cosmetics for example, skin lightening agents, moisturizers, antioxidants, oil components, UV absorbers, surfactants, Adhesives, alcohols, powder components, coloring materials, aqueous components, water, various skin nutrients and the like can be appropriately blended as needed.
  • the cosmetics include all cosmetics applied to the skin of animals (including humans), mucous membranes, body hair, hair, scalp, nails, teeth, skins, lips and the like.
  • cosmetic formulations including aqueous solutions, solubilized, emulsifying, powder, oil-based, gel-based, ointment-based, aerosol-based, water-oil two-layer, water-oil-powder three-layer, etc. It can take a dosage form.
  • cosmetics are also arbitrary, and for example, in the case of basic cosmetics, there may be mentioned face wash, lotion, milk, cream, gel, essence, essence, pack, mask etc., and in the case of makeup cosmetics, foundation, Lipsticks, blushers, eye shadows, eyeliners, mascaras, etc. may be mentioned, and in the case of nail cosmetics, manicures, base coats, top coats, light removal liquids etc.
  • the above royal jelly, propolis and pomegranate or an extract thereof can be used as it is, and, if necessary, minerals, vitamins, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential Fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants, flavors, stabilizers, preservatives, sustained release modifiers, surfactants, solubilizers, wetting agents, etc. it can.
  • Food and drink include any food and drink that animals (including humans) can consume.
  • the types of food and drink are not particularly limited, and, for example, dairy products; fermented foods (yogurt, royal jelly, etc.); beverages (coffee, juice, soft drinks such as tea beverages, milk drinks, lactic acid bacteria drinks, lactic acid bacteria-containing drinks, Yogurt drink, carbonated drink, sake, liquor, liquor such as fruit liquor) spreads (custard cream etc); pastes (fruit paste etc); Western confectionery (chocolate, donut, pie, shoe cream, gum, jelly, Candy, cookies, cakes, puddings, etc .; Japanese confectionery (Daifuku, rice cakes, buns, castellas, antels, lambs etc.); Ice confectionery (ice cream, ice candy, sherbet etc.); Foods (curry, beef porridge, risotto, Miso soup, soup, meat sauce, pasta, pickles, jam etc); seasonings (dressing, sprinkle, umami seasoning, soup ingredients etc) It is below
  • the manufacturing method of the food-drinks of this invention is not specifically limited, either, It can follow the well-known method suitably.
  • the dosage unit form for use as a supplement is not particularly limited and can be appropriately selected, and examples thereof include tablets, capsules, granules, solutions, powders and the like.
  • the intake amount of the food and drink of the present invention can be appropriately set according to various conditions such as the weight, age, sex and symptoms of the user.
  • composition of the present invention and the mTOR inhibitor are prepared as a medicament
  • the above royal jelly, propolis and pomegranate or an extract thereof is used together with a nontoxic carrier, diluent or excipient acceptable for Tablets, sugar-coated tablets, effervescent tablets, film-coated tablets, chewable tablets, troches, etc., capsules, pills, powders (powders), fine granules, granules, solutions, suspensions, emulsions, It is possible to prepare in the form of syrup, paste and the like, for example, for preparation of pharmaceutical (for oral).
  • the dose of the pharmaceutical can be determined appropriately according to various conditions such as the weight, age, sex and symptoms of the patient.
  • the pharmaceuticals and cosmetics of the present invention also include quasi drugs.
  • composition of the present invention and the mTOR inhibitor described above apply to mammals (preferably humans) including humans.
  • composition of the present invention and the mTOR inhibitor have an excellent mTOR inhibitory action due to the synergistic effect of royal jelly or propolis and pomegranate or its extract.
  • the combination of royal jelly or propolis with pomegranate or its extract is an mTOR inhibitor, and for anti-aging, anti-fatigue, anti-stress, metabolic improvement, diet, moisturizing, skin amelioration or gloss improvement It is useful as a component of a composition for preventing cognitive function deterioration, for immunosuppression, for anti-allergy, for cancer prevention, or for suppressing cancer progression.
  • composition of the present invention and the mTOR inhibitor have high safety because they contain a naturally derived component as an active ingredient.
  • Types of cancer include gastric cancer, colon cancer (rectum cancer, colon cancer), small intestine cancer, liver cancer, pancreas cancer, lung cancer, pharyngeal cancer, esophageal cancer, renal cancer, gallbladder and cholangiocarcinoma, head and neck cancer, bladder cancer Prostate cancer, breast cancer, uterine cancer (cervical cancer, endometrial cancer), ovarian cancer, brain cancer, leukemia, malignant lymphoma, multiple myeloma and the like.
  • Test Example ⁇ Material> Raw royal jelly (non-enzyme treated), enzyme-treated royal jelly and lyophilized powder of propolis ethanol extract were dissolved in DMSO and used for the test.
  • the enzyme-treated royal jelly is obtained by lyophilizing and grinding the ethanol extract of Alexin Propolis bulk (produced in Minas Gerais State, Brazil) by the method described in Example 1 of Patent No. 3994120, and the ethanol extract powder of propolis is obtained by lyophilization
  • Alexin Propolis bulk produced in Minas Gerais State, Brazil
  • Pomegranate (A) A pomegranate purchased from the central market of Aracaju City, Sergipe, State of Northeast Brazil, was used. Pomegranate peel was placed in a mill and finely ground, and 25 ml of 80% EtOH (using specific alcohol traceable (95% EtOH)) was added to 5 g of pomegranate peel and shaken overnight with a shaker (room temperature). Then, it centrifuged at 3,000 rpm and 25 degreeC for 15 minutes, filtered the supernatant liquid, and collect
  • An equivalent mixture of pomegranate (B) and DMSO, pomegranate (B) and royal jelly, pomegranate (B) and propolis, respectively, is prepared 5 times using DMSO, propolis, pomegranate (B) and propolis mixture are 4 stages (15 , 3, 0.6, 0.12 ⁇ g / mL), royal jelly, pomegranate (B), pomegranate (B) and royal jelly mixture are diluted in 6 steps (15, 3, 0.6, 0.12, 0.024, 0.0048 ⁇ g / mL) and used as test samples did.
  • Chemiluminescent reagent 2 or (Clarity TM Western ECL Substrate, BIO -RAD # 170-5060) were mixed in equal amounts and then left to stand for 5 minutes and rub on the lap, Lumino image analyzer (LAS-3000 sandwiched hybridization bag It measured using mini, FujiFilm).
  • results of Western blotting are shown in FIG.
  • the higher the mTOR activity the darker the spots appear.
  • the three side-by-side spots in the color frame are spots of the same condition.
  • the results of m-TOR inhibitor PI-103 are shown and compared. Taking a spot at 0.6 ⁇ g / mL as an example, compared to the spot with royal jelly, propolis and pomegranate (B) alone, the spot density is thinner in the sample in which the royal jelly or propolis is added to pomegranate, Western blotting
  • the dot plot also confirmed a synergistic and dose dependent inhibition of mTOR.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)

Abstract

L'invention concerne : une composition comprenant de la gelée royale et du péricarpe de grenade ou un extrait de celle-ci, ladite composition étant un produit cosmétique, un aliment, une boisson, un médicament ou un quasi-médicament; une composition comprenant de la propolis et de la grenade ou un extrait de celle-ci, ladite composition étant un produit cosmétique, un aliment, une boisson, un médicament ou un quasi-médicament; un inhibiteur de mTOR comprenant de la gelée royale et/ou de la propolis et de la grenade ou un extrait de celle-ci; et une composition contre le vieillissement, contre la fatigue, contre le stress, pour améliorer le métabolisme, pour suivre un régime, pour l'humidification, pour améliorer la fermeté ou la brillance de la peau, pour prévenir une déficience cognitive, pour une immunosuppression, contre une allergie, pour prévenir le cancer ou pour inhiber la progression du cancer, ladite composition comprenant de la gelée royale et/ou de la propolis et de la grenade ou un extrait de celle-ci.
PCT/JP2019/002187 2018-01-26 2019-01-24 INHIBITEUR DE mTOR WO2019146669A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019567128A JP7256542B2 (ja) 2018-01-26 2019-01-24 ｍＴＯＲ阻害剤
CN201980009955.4A CN111655226A (zh) 2018-01-26 2019-01-24 mTOR抑制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018011840 2018-01-26
JP2018-011840 2018-01-26

Publications (1)

Publication Number Publication Date
WO2019146669A1 true WO2019146669A1 (fr) 2019-08-01

Family

ID=67395586

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/002187 WO2019146669A1 (fr) 2018-01-26 2019-01-24 INHIBITEUR DE mTOR

Country Status (4)

Country Link
JP (1) JP7256542B2 (fr)
CN (1) CN111655226A (fr)
TW (1) TW201932128A (fr)
WO (1) WO2019146669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019137627A (ja) * 2018-02-08 2019-08-22 株式会社サニープレイス ヘアカラー方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793922B (zh) * 2021-12-14 2023-02-21 彥臣生技藥品股份有限公司 一種用於提升認知能力之組合物及其用途

Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040003929A (ko) * 2002-07-05 2004-01-13 노재목 알레르기 치료용 액상 추출차의 조성물
JP2008184424A (ja) * 2007-01-30 2008-08-14 Kao Corp 水性毛髪洗浄剤
KR20090030905A (ko) * 2007-09-21 2009-03-25 주식회사 쌍용씨앤비 기능성 물질을 함유하는 일회용 흡수제품
JP2009173586A (ja) * 2008-01-25 2009-08-06 Kao Corp 毛髪洗浄剤
KR20100123424A (ko) * 2009-05-15 2010-11-24 황철수 파래가 함유된 금연 보조형 치약 조성물 및 그 제조방법
CN102038903A (zh) * 2010-09-02 2011-05-04 景松森 治疗急性胃肠炎的中药
CN102068512A (zh) * 2009-11-19 2011-05-25 范琛 黄槐胶囊
CN102319288A (zh) * 2011-08-31 2012-01-18 青岛绿曼生物工程有限公司 一种治疗家禽传染性法氏囊病的纯中药组合物及其制备方法
CN102600457A (zh) * 2011-12-22 2012-07-25 青岛绿曼生物工程有限公司 一种治疗猪病毒性腹泻的复方蜂胶组合物及其制备方法
CN103045417A (zh) * 2011-10-11 2013-04-17 唐淑娟 一种红石榴植物皂
CN103160399A (zh) * 2011-12-09 2013-06-19 赵英 一种纯天然植物皂
CN103211025A (zh) * 2013-03-30 2013-07-24 马鞍山市黄池食品（集团）有限公司 一种抗疲劳豆浆及其制作方法
CN103251022A (zh) * 2013-04-18 2013-08-21 石台县山园食品有限公司 一种当归调味料及其生产方法
CN103404756A (zh) * 2013-05-27 2013-11-27 胡安然 一种肠胃炎患者食用的特殊膳食
CN103918744A (zh) * 2014-03-19 2014-07-16 柳培健 一种蜂胶核桃煎饼
CN104026599A (zh) * 2014-04-26 2014-09-10 侯道鸿 一种葱香兔肉及其制备方法
CN104274498A (zh) * 2014-09-18 2015-01-14 开平健之源保健食品有限公司 一种高效抗肿瘤灵芝提取物及其制备方法
CN104367529A (zh) * 2014-11-19 2015-02-25 苏州佑君环境科技有限公司 空气净化用驱蚊花露水及其制备方法
CN104398796A (zh) * 2014-11-04 2015-03-11 孙怡 一种渗出性皮肤病用湿敷剂及其制备方法
CN104886590A (zh) * 2015-04-25 2015-09-09 安徽蜂献蜂业有限公司 一种天然蜂胶抗氧化剂及其制备方法
KR101581334B1 (ko) * 2015-04-22 2015-12-31 (주)라파프로폴리스 수용성 프로폴리스 추출액과 석류 농축액을 이용한 기능성 두부의 제조방법
CN105230925A (zh) * 2015-09-29 2016-01-13 明光市农源农作物专业合作社 一种具有健胃消食功效的猕猴桃果脯及其制备方法
CN105287897A (zh) * 2015-09-07 2016-02-03 天津市康瑞药业有限公司 一种适用于更年期女性的复合维生素补充片剂
CN105325664A (zh) * 2015-09-29 2016-02-17 明光市农源农作物专业合作社 一种红枣阿胶益气补血猕猴桃果脯及其制备方法
CN105558017A (zh) * 2015-12-28 2016-05-11 芜湖润蓝生物科技有限公司 一种玫瑰养血乳酸饮料
CN105613709A (zh) * 2016-04-05 2016-06-01 连云港恒图农牧开发有限公司 一种具有优异保鲜性能的猪肉保鲜剂及其制备方法
CN105995825A (zh) * 2016-06-24 2016-10-12 安徽省丰康农业科技有限公司 一种能提高免疫力的蜂王浆口服制剂及其制备方法
CN106262353A (zh) * 2016-07-19 2017-01-04 丁志强 石榴桑葚膏生产方法
CN106491494A (zh) * 2016-11-25 2017-03-15 江苏爱西施科技服务咨询股份有限公司 一种蚕丝保湿护肤品及其制备方法
CN106619438A (zh) * 2016-11-17 2017-05-10 东莞波顿香料有限公司 一种植物源抑菌剂及含有该植物源抑菌剂的洗手液和牙膏
CN106721727A (zh) * 2016-12-24 2017-05-31 郭海峰 防治糖尿病的饮料及其制备方法
CN106942342A (zh) * 2017-01-17 2017-07-14 广西神龙王农牧食品集团有限公司 一种陆川猪肉的保鲜方法
CN107242505A (zh) * 2017-08-09 2017-10-13 安徽省奇圣养蜂专业合作社 一种具有美容养颜功效的保健蜂蜜及其制备方法
CN107372807A (zh) * 2017-08-31 2017-11-24 广西吉朋投资有限公司 一种蔬菜保鲜剂及其制备方法
CN107410473A (zh) * 2017-04-21 2017-12-01 陈建峰 一种可食用保鲜果蜡的制备方法
CN107668183A (zh) * 2017-11-02 2018-02-09 广西吉朋投资有限公司 一种肉制品保鲜剂
CN108013385A (zh) * 2017-12-12 2018-05-11 苏州卫生职业技术学院 一种免疫力增强制剂的制备方法
CN108478459A (zh) * 2018-04-28 2018-09-04 广东巴松那生物科技有限公司 一种含乳酸杆菌发酵溶胞产物的眼部精华及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000143491A (ja) * 1998-11-06 2000-05-23 Pola Chem Ind Inc 老化用の化粧料
JP4658290B2 (ja) * 2000-06-26 2011-03-23 丸善製薬株式会社 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
JP2002003393A (ja) * 2000-06-26 2002-01-09 Maruzen Pharmaceut Co Ltd 線維芽細胞増殖作用剤、美容用飲食品および皮膚化粧料
JP4658348B2 (ja) * 2001-02-02 2011-03-23 丸善製薬株式会社 コラーゲン産生促進剤、コラゲナーゼ阻害剤、線維芽細胞増殖作用剤、エラスターゼ阻害剤、エストロゲン様作用剤、並びに皮膚化粧料
JP4889068B2 (ja) * 2001-04-02 2012-02-29 丸善製薬株式会社 ヒスタミン遊離抑制剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、活性酸素消去剤およびラジカル消去剤

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040003929A (ko) * 2002-07-05 2004-01-13 노재목 알레르기 치료용 액상 추출차의 조성물
JP2008184424A (ja) * 2007-01-30 2008-08-14 Kao Corp 水性毛髪洗浄剤
KR20090030905A (ko) * 2007-09-21 2009-03-25 주식회사 쌍용씨앤비 기능성 물질을 함유하는 일회용 흡수제품
JP2009173586A (ja) * 2008-01-25 2009-08-06 Kao Corp 毛髪洗浄剤
KR20100123424A (ko) * 2009-05-15 2010-11-24 황철수 파래가 함유된 금연 보조형 치약 조성물 및 그 제조방법
CN102068512A (zh) * 2009-11-19 2011-05-25 范琛 黄槐胶囊
CN102038903A (zh) * 2010-09-02 2011-05-04 景松森 治疗急性胃肠炎的中药
CN102319288A (zh) * 2011-08-31 2012-01-18 青岛绿曼生物工程有限公司 一种治疗家禽传染性法氏囊病的纯中药组合物及其制备方法
CN103045417A (zh) * 2011-10-11 2013-04-17 唐淑娟 一种红石榴植物皂
CN103160399A (zh) * 2011-12-09 2013-06-19 赵英 一种纯天然植物皂
CN102600457A (zh) * 2011-12-22 2012-07-25 青岛绿曼生物工程有限公司 一种治疗猪病毒性腹泻的复方蜂胶组合物及其制备方法
CN103211025A (zh) * 2013-03-30 2013-07-24 马鞍山市黄池食品（集团）有限公司 一种抗疲劳豆浆及其制作方法
CN103251022A (zh) * 2013-04-18 2013-08-21 石台县山园食品有限公司 一种当归调味料及其生产方法
CN103404756A (zh) * 2013-05-27 2013-11-27 胡安然 一种肠胃炎患者食用的特殊膳食
CN103918744A (zh) * 2014-03-19 2014-07-16 柳培健 一种蜂胶核桃煎饼
CN104026599A (zh) * 2014-04-26 2014-09-10 侯道鸿 一种葱香兔肉及其制备方法
CN104274498A (zh) * 2014-09-18 2015-01-14 开平健之源保健食品有限公司 一种高效抗肿瘤灵芝提取物及其制备方法
CN104398796A (zh) * 2014-11-04 2015-03-11 孙怡 一种渗出性皮肤病用湿敷剂及其制备方法
CN104367529A (zh) * 2014-11-19 2015-02-25 苏州佑君环境科技有限公司 空气净化用驱蚊花露水及其制备方法
KR101581334B1 (ko) * 2015-04-22 2015-12-31 (주)라파프로폴리스 수용성 프로폴리스 추출액과 석류 농축액을 이용한 기능성 두부의 제조방법
CN104886590A (zh) * 2015-04-25 2015-09-09 安徽蜂献蜂业有限公司 一种天然蜂胶抗氧化剂及其制备方法
CN105287897A (zh) * 2015-09-07 2016-02-03 天津市康瑞药业有限公司 一种适用于更年期女性的复合维生素补充片剂
CN105230925A (zh) * 2015-09-29 2016-01-13 明光市农源农作物专业合作社 一种具有健胃消食功效的猕猴桃果脯及其制备方法
CN105325664A (zh) * 2015-09-29 2016-02-17 明光市农源农作物专业合作社 一种红枣阿胶益气补血猕猴桃果脯及其制备方法
CN105558017A (zh) * 2015-12-28 2016-05-11 芜湖润蓝生物科技有限公司 一种玫瑰养血乳酸饮料
CN105613709A (zh) * 2016-04-05 2016-06-01 连云港恒图农牧开发有限公司 一种具有优异保鲜性能的猪肉保鲜剂及其制备方法
CN105995825A (zh) * 2016-06-24 2016-10-12 安徽省丰康农业科技有限公司 一种能提高免疫力的蜂王浆口服制剂及其制备方法
CN106262353A (zh) * 2016-07-19 2017-01-04 丁志强 石榴桑葚膏生产方法
CN106619438A (zh) * 2016-11-17 2017-05-10 东莞波顿香料有限公司 一种植物源抑菌剂及含有该植物源抑菌剂的洗手液和牙膏
CN106491494A (zh) * 2016-11-25 2017-03-15 江苏爱西施科技服务咨询股份有限公司 一种蚕丝保湿护肤品及其制备方法
CN106721727A (zh) * 2016-12-24 2017-05-31 郭海峰 防治糖尿病的饮料及其制备方法
CN106942342A (zh) * 2017-01-17 2017-07-14 广西神龙王农牧食品集团有限公司 一种陆川猪肉的保鲜方法
CN107410473A (zh) * 2017-04-21 2017-12-01 陈建峰 一种可食用保鲜果蜡的制备方法
CN107242505A (zh) * 2017-08-09 2017-10-13 安徽省奇圣养蜂专业合作社 一种具有美容养颜功效的保健蜂蜜及其制备方法
CN107372807A (zh) * 2017-08-31 2017-11-24 广西吉朋投资有限公司 一种蔬菜保鲜剂及其制备方法
CN107668183A (zh) * 2017-11-02 2018-02-09 广西吉朋投资有限公司 一种肉制品保鲜剂
CN108013385A (zh) * 2017-12-12 2018-05-11 苏州卫生职业技术学院 一种免疫力增强制剂的制备方法
CN108478459A (zh) * 2018-04-28 2018-09-04 广东巴松那生物科技有限公司 一种含乳酸杆菌发酵溶胞产物的眼部精华及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019137627A (ja) * 2018-02-08 2019-08-22 株式会社サニープレイス ヘアカラー方法
JP6994970B2 (ja) 2018-02-08 2022-01-14 株式会社サニープレイス ヘアカラー方法

Also Published As

Publication number Publication date
JPWO2019146669A1 (ja) 2021-01-28
TW201932128A (zh) 2019-08-16
JP7256542B2 (ja) 2023-04-12
CN111655226A (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
JP4205188B2 (ja) メイラード反応阻害剤
JP5468757B2 (ja) 線維芽細胞増殖促進能を有する組成物
JP2008007419A (ja) 鶏卵卵殻膜を原料とするタンパク質分解酵素による卵殻膜加水分解物とその製法、並びにこれらを添加した機能物
JP2008137998A (ja) 皮膚改善剤及び美容健康用経口組成物
JP2008291004A (ja) 美肌用組成物
JP2009263279A (ja) エラスターゼ阻害剤
JP7406839B2 (ja) 皮膚外用剤
WO2021005941A1 (fr) Composition contenant un extrait d'albizia julibrissin
JP2004115438A (ja) 抗老化用組成物
WO2019146669A1 (fr) INHIBITEUR DE mTOR
JP6049381B2 (ja) 養蜂産品を含むグネツム組成物
KR101437997B1 (ko) 생캐비어 발효추출물 및 이를 함유하는 피부화장료
JPWO2020054204A1 (ja) 抗酸化剤
KR20200042000A (ko) 간보호, 숙취해소, 항산화 및 항염증 효능을 갖는 펩티드
JP7461034B2 (ja) 間葉系幹細胞増殖剤
KR102359692B1 (ko) 박대 껍질 추출물을 유효성분으로 포함하는 피부노화 방지 및 주름 개선용 조성물
KR102255499B1 (ko) 신규 항산화 펩타이드 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
JP2022108114A (ja) オートファジー誘導剤
JP2023116711A (ja) ｍＴＯＲ阻害剤
KR20170037545A (ko) 굴 가수분해물의 제조방법 및 이로부터 분리된 펩타이드
US10894067B2 (en) Genome stability enhancer
KR101694833B1 (ko) 누에 유래 가수분해물을 포함하는 화장료 조성물 및 식품 조성물
KR102615763B1 (ko) 저분자 흑염소육골즙 효소분해물 및 유효 펩타이드 서열을 함유하는 조성물
JP7262319B2 (ja) メラニン生成抑制剤、及びメラニン生成抑制剤の製造方法
EP4118978A1 (fr) Composition orale pour inhiber l'élastase et son utilisation, inhibiteur de l'élastase, et procédé d'inhibition de l'activité de l'élastase par ingestion orale d'un inhibiteur de l'élastase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19743372

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019567128

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19743372

Country of ref document: EP

Kind code of ref document: A1